How PD-1 promotes Merkel cell carcinoma progression
Inhibiting mTOR signalling and neutralising mtROS suppressed MCC-PD-1-mediated tumour proliferation in mice.
List view / Grid view
Inhibiting mTOR signalling and neutralising mtROS suppressed MCC-PD-1-mediated tumour proliferation in mice.
AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
Researchers explored the effects of loops and 3D genome organisation on gene silencing, and found that ‘cohesinopathies’ may be linked it.
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.
The new study’s findings suggest that CRS can be treated with an IL-6 receptor antibody that has a short half-life.
Researchers observed many quantifiable differences between diseased cells made from affected children and their gene-edited cells.
Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.
Researchers discover a key metabolic process that cancer cells use to grow in a nutrient deprived environment, which could be a new target.
A potential link between truncating variants and the development of DCM has been found, and a patient-focused registry about PPCM was made.
Oligodendrocyte precursor cells and the synapses they form with neurons could be relevant to many disease conditions, including cancer.
Using clinical E. coli bacteraemia isolates, researchers found that high-persister mutants evolved which contributed to antibiotic failure.
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
Genetic factors that promote disease development accumulated in CD4+ T cells exhibiting specific gene programmes.
Genetic engineering created IgA antibodies that bind to the SARS-CoV-2 spike protein in a similar way to IgG antibodies.